A G Euser1, T D Metz1,2, A A Allshouse3, K D Heyborne1,2. 1. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO, USA. 2. Denver Health Medical Center, Department of Obstetrics and Gynecology, Denver, CO, USA. 3. University of Colorado School of Public Health, Aurora, CO, USA.
Abstract
OBJECTIVE: The objective of the study is to evaluate low-dose aspirin (LDA) for pre-eclampsia prevention in twin gestations with elevated maternal serum human chorionic gonadotropin (hCG). STUDY DESIGN: Secondary analysis of the Maternal-Fetal Medicine Units High-Risk Aspirin trial for pre-eclampsia prevention. A threshold hCG level for predicting pre-eclampsia was identified in placebo-randomized patients. Pre-eclampsia incidence and time of onset were compared between treatment groups, overall and by hCG threshold category. RESULTS:Pre-eclampsia incidence was lower with LDA than with placebo (6% vs 16%, OR 0.32, 95% CI 0.12 to 0.82). An hCG threshold of 29.96 IU ml(-1) best predicted pre-eclampsia. In patients with hCG <29.96IU ml(-1), the differences in pre-eclampsia incidence or time of onset were not significant. In patients with hCG >29.96 IU ml(-1), LDA was associated with lower pre-eclampsia incidence than placebo (6% vs 23%, OR 0.21, 95% CI 0.06 to 0.79) and delayed onset. CONCLUSION: Twin gestations with elevated hCG levels may benefit from LDA for pre-eclampsia prevention.
RCT Entities:
OBJECTIVE: The objective of the study is to evaluate low-dose aspirin (LDA) for pre-eclampsia prevention in twin gestations with elevated maternal serum human chorionic gonadotropin (hCG). STUDY DESIGN: Secondary analysis of the Maternal-Fetal Medicine Units High-Risk Aspirin trial for pre-eclampsia prevention. A threshold hCG level for predicting pre-eclampsia was identified in placebo-randomized patients. Pre-eclampsia incidence and time of onset were compared between treatment groups, overall and by hCG threshold category. RESULTS: Pre-eclampsia incidence was lower with LDA than with placebo (6% vs 16%, OR 0.32, 95% CI 0.12 to 0.82). An hCG threshold of 29.96 IU ml(-1) best predicted pre-eclampsia. In patients with hCG <29.96 IU ml(-1), the differences in pre-eclampsia incidence or time of onset were not significant. In patients with hCG >29.96 IU ml(-1), LDA was associated with lower pre-eclampsia incidence than placebo (6% vs 23%, OR 0.21, 95% CI 0.06 to 0.79) and delayed onset. CONCLUSION: Twin gestations with elevated hCG levels may benefit from LDA for pre-eclampsia prevention.
Authors: Lorraine Dugoff; John C Hobbins; Fergal D Malone; John Vidaver; Lisa Sullivan; Jacob A Canick; Geralyn M Lambert-Messerlian; T Flint Porter; David A Luthy; Christine H Comstock; George Saade; Keith Eddleman; Irwin R Merkatz; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Mary E D'Alton Journal: Obstet Gynecol Date: 2005-08 Impact factor: 7.661
Authors: Sharon E Maynard; Sybil L Crawford; Susanne Bathgate; Jing Yan; Laura Robidoux; Melissa Moore; Tiffany A Moore Simas Journal: Am J Obstet Gynecol Date: 2013-03-18 Impact factor: 8.661
Authors: Baha Sibai; Roberto Romero; Mark A Klebanoff; Madeline Murguia Rice; Steve Caritis; Marshall D Lindheimer; J Peter Van Dorsten; Mark Landon; Menachem Miodovnik; Mitchell Dombrowski; Paul Meis Journal: Am J Obstet Gynecol Date: 2009-06 Impact factor: 8.661
Authors: Carlos Palma; Jessica Jellins; Andrew Lai; Alexis Salas; America Campos; Shayna Sharma; Gregory Duncombe; Jon Hyett; Carlos Salomon Journal: Subcell Biochem Date: 2021